Acelyrin (NASDAQ:SLRN) PT Raised to $15.00

Acelyrin (NASDAQ:SLRN - Free Report) had its price objective lifted by Wells Fargo & Company from $13.00 to $15.00 in a research report released on Wednesday, Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other analysts also recently issued reports on SLRN. Morgan Stanley decreased their price objective on shares of Acelyrin from $13.00 to $6.00 and set an "equal weight" rating for the company in a report on Monday, August 19th. Piper Sandler decreased their price target on shares of Acelyrin from $68.00 to $20.00 and set an "overweight" rating for the company in a research note on Wednesday, August 14th. Finally, HC Wainwright downgraded Acelyrin from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $18.00 to $6.00 in a research note on Wednesday, August 14th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $11.17.

Acelyrin Stock Performance

Shares of Acelyrin stock traded up $0.36 during mid-day trading on Wednesday, hitting $6.08. 1,427,916 shares of the stock were exchanged, compared to its average volume of 1,080,815. The company has a market capitalization of $606.84 million, a P/E ratio of -2.08 and a beta of 2.33. The company has a 50-day simple moving average of $4.82 and a 200 day simple moving average of $4.92. Acelyrin has a 12 month low of $3.36 and a 12 month high of $10.70.

Acelyrin (NASDAQ:SLRN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.08). During the same period last year, the firm earned ($0.56) earnings per share. Analysts predict that Acelyrin will post -3.08 EPS for the current year.

Institutional Investors Weigh In On Acelyrin

Several institutional investors have recently made changes to their positions in SLRN. SG Americas Securities LLC lifted its holdings in shares of Acelyrin by 129.6% in the third quarter. SG Americas Securities LLC now owns 26,755 shares of the company's stock worth $132,000 after buying an additional 15,101 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in Acelyrin by 158.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 90,022 shares of the company's stock worth $397,000 after acquiring an additional 55,141 shares during the period. Almitas Capital LLC purchased a new stake in Acelyrin in the 2nd quarter worth approximately $1,659,000. Susquehanna Fundamental Investments LLC bought a new position in Acelyrin in the 2nd quarter valued at $706,000. Finally, Blue Owl Capital Holdings LP grew its position in shares of Acelyrin by 3.5% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 2,926,028 shares of the company's stock valued at $12,904,000 after purchasing an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 87.31% of the company's stock.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.